Kevin DeGeeter and James Colby

Following the presentation of encouraging pre-clinical data from Novavax, Inc. (NASDAQ: NVAX)'s nanoparticle influenza vaccine, Ladenburg Thalmann upgraded shares of the company. The rating on the stock now goes from Neutral to Buy, with a $1.60 price target. The shares of Novavax were trading up 1...